摘要
目的:分析乳腺癌患者应用内分泌药物后发生脂肪肝的机理及预防。方法:收集住院及门诊服用内分泌药物治疗的乳腺癌患者,通过血脂、腹部CT或B超检查,探讨合并脂肪肝的机理。结果:107例患者均有不同程度的脂肪肝发生,轻度脂肪肝42例,中度脂肪肝37例,重度脂肪肝28例。中断内分泌治疗13例。最早发生脂肪肝服药3月,最晚服药近2年,平均13月。结论:乳腺癌服用内分泌治疗的患者应注意预防脂肪肝的发生并给予及早的干预治疗。
Objective：To analyze the feature on fatty liver in patients with breast cancer with endocrine therapy ive the Interventions.Methods： Total of 107 breast cancer patients with endocrine therapy with fatty liver,were tested by lipid/CT/ B-doppler.Results： Of 107cases,suffering from fatty liver,42 cases of mild fatty liver,37 cases of moderate fatty liver,28 cases of severe fatty liver.Stopping treatment in 13 cases.Fatty liver developed earliest 3 months after treatment,the latest took place almost 2 years after treatment.Conclusion： Endocrine therapy in breast cancer patients should pay attention to prevent fatty liver and provide early intervention therapy.
出处
《现代肿瘤医学》
CAS
2012年第5期980-981,共2页
Journal of Modern Oncology
关键词
乳腺癌
内分泌治疗
脂肪肝
breast cancer
endocrine therapy
fatty liver
